Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending
In the field of general medicine, class effects, or therapeutic interchangeability, have been declared for several families of drugs including statins, calcium channel blockers and ACE inhibitors. The existence of such class effects enables healthcare payers to negotiate for substantially lower drug...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-07-01
|
| Series: | BMJ Oncology |
| Online Access: | https://bmjoncology.bmj.com/content/3/1/e000287.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832581521143234560 |
|---|---|
| author | Gregory R Pond Ian F Tannock Daniel A Goldstein Leonard B Saltz |
| author_facet | Gregory R Pond Ian F Tannock Daniel A Goldstein Leonard B Saltz |
| author_sort | Gregory R Pond |
| collection | DOAJ |
| description | In the field of general medicine, class effects, or therapeutic interchangeability, have been declared for several families of drugs including statins, calcium channel blockers and ACE inhibitors. The existence of such class effects enables healthcare payers to negotiate for substantially lower drug prices, thereby reducing financial toxicity, both at an individual and societal levels. Until now, the existence of class effects in oncology has been considered rare. Here, we review evidence from clinical trials that supports the existence of class effects for several types of anticancer drugs. These class effects in oncology should be exploited to reduce healthcare costs. |
| format | Article |
| id | doaj-art-861132a319e645919ea21c894d139add |
| institution | Kabale University |
| issn | 2752-7948 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Oncology |
| spelling | doaj-art-861132a319e645919ea21c894d139add2025-01-30T10:10:09ZengBMJ Publishing GroupBMJ Oncology2752-79482024-07-013110.1136/bmjonc-2023-000287Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spendingGregory R Pond0Ian F Tannock1Daniel A Goldstein2Leonard B Saltz3Biostatistics, McMaster University, Hamilton, Ontario, CanadaPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaMedical Oncology, Rabin Medical Center Davidoff Cancer Center, Petah Tikva, Central, IsraelMedical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USAIn the field of general medicine, class effects, or therapeutic interchangeability, have been declared for several families of drugs including statins, calcium channel blockers and ACE inhibitors. The existence of such class effects enables healthcare payers to negotiate for substantially lower drug prices, thereby reducing financial toxicity, both at an individual and societal levels. Until now, the existence of class effects in oncology has been considered rare. Here, we review evidence from clinical trials that supports the existence of class effects for several types of anticancer drugs. These class effects in oncology should be exploited to reduce healthcare costs.https://bmjoncology.bmj.com/content/3/1/e000287.full |
| spellingShingle | Gregory R Pond Ian F Tannock Daniel A Goldstein Leonard B Saltz Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending BMJ Oncology |
| title | Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending |
| title_full | Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending |
| title_fullStr | Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending |
| title_full_unstemmed | Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending |
| title_short | Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending |
| title_sort | pharmacological class effects of anticancer drugs opportunities for decreasing healthcare spending |
| url | https://bmjoncology.bmj.com/content/3/1/e000287.full |
| work_keys_str_mv | AT gregoryrpond pharmacologicalclasseffectsofanticancerdrugsopportunitiesfordecreasinghealthcarespending AT ianftannock pharmacologicalclasseffectsofanticancerdrugsopportunitiesfordecreasinghealthcarespending AT danielagoldstein pharmacologicalclasseffectsofanticancerdrugsopportunitiesfordecreasinghealthcarespending AT leonardbsaltz pharmacologicalclasseffectsofanticancerdrugsopportunitiesfordecreasinghealthcarespending |